vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and 17 Education & Technology Group Inc. (YQ). Click either name above to swap in a different company.

FATE THERAPEUTICS INC is the larger business by last-quarter revenue ($1.4M vs $1.2M, roughly 1.2× 17 Education & Technology Group Inc.).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

McGraw Hill, Inc. is an American education science company that provides educational content, software, and services for students and educators across various levels—from K-12 to higher education and professional settings. They produce textbooks, digital learning tools, and adaptive technology to enhance learning experiences and outcomes. It is one of the "big three" educational publishers along with Houghton Mifflin Harcourt and Pearson Education. McGraw Hill also publishes reference and tra...

FATE vs YQ — Head-to-Head

Bigger by revenue
FATE
FATE
1.2× larger
FATE
$1.4M
$1.2M
YQ

Income Statement — Q4 FY2025 vs Q3 FY2024

Metric
FATE
FATE
YQ
YQ
Revenue
$1.4M
$1.2M
Net Profit
$-342.2K
Gross Margin
60.9%
Operating Margin
-36.3%
Net Margin
-29.2%
Revenue YoY
-26.4%
Net Profit YoY
37.9%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
YQ
YQ
Q4 25
$1.4M
Q3 25
$1.7M
Q2 25
$1.9M
Q1 25
$1.6M
Q4 24
$1.9M
Q3 24
$3.1M
$1.2M
Q2 24
$6.8M
$1.3M
Q1 24
$1.9M
Net Profit
FATE
FATE
YQ
YQ
Q4 25
Q3 25
$-32.3M
Q2 25
$-34.1M
Q1 25
$-37.6M
Q4 24
Q3 24
$-47.7M
$-342.2K
Q2 24
$-38.4M
$-1.1M
Q1 24
$-48.0M
Gross Margin
FATE
FATE
YQ
YQ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
60.9%
Q2 24
16.0%
Q1 24
Operating Margin
FATE
FATE
YQ
YQ
Q4 25
Q3 25
-1995.1%
Q2 25
-1938.5%
Q1 25
-2534.1%
Q4 24
Q3 24
-1703.9%
-36.3%
Q2 24
-665.7%
-89.2%
Q1 24
-2652.9%
Net Margin
FATE
FATE
YQ
YQ
Q4 25
Q3 25
-1852.4%
Q2 25
-1786.6%
Q1 25
-2309.5%
Q4 24
Q3 24
-1551.0%
-29.2%
Q2 24
-567.4%
-82.5%
Q1 24
-2493.7%
EPS (diluted)
FATE
FATE
YQ
YQ
Q4 25
Q3 25
$-0.27
Q2 25
$-0.29
Q1 25
$-0.32
Q4 24
Q3 24
$-0.40
Q2 24
$-0.33
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
YQ
YQ
Cash + ST InvestmentsLiquidity on hand
$203.7M
$38.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.2M
$7.9M
Total Assets
$318.9M
$76.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
YQ
YQ
Q4 25
$203.7M
Q3 25
$215.4M
Q2 25
$222.8M
Q1 25
$240.4M
Q4 24
$279.1M
Q3 24
$296.9M
$38.7M
Q2 24
$304.9M
$48.2M
Q1 24
$121.3M
Stockholders' Equity
FATE
FATE
YQ
YQ
Q4 25
$207.2M
Q3 25
$234.1M
Q2 25
$261.4M
Q1 25
$288.4M
Q4 24
$318.7M
Q3 24
$362.3M
$7.9M
Q2 24
$397.0M
$7.9M
Q1 24
$426.1M
Total Assets
FATE
FATE
YQ
YQ
Q4 25
$318.9M
Q3 25
$343.7M
Q2 25
$371.6M
Q1 25
$398.7M
Q4 24
$440.7M
Q3 24
$495.0M
$76.7M
Q2 24
$528.8M
$81.2M
Q1 24
$569.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
YQ
YQ
Operating Cash FlowLast quarter
$-106.1M
Free Cash FlowOCF − Capex
$-112.0M
FCF MarginFCF / Revenue
-8183.9%
Capex IntensityCapex / Revenue
434.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
YQ
YQ
Q4 25
$-106.1M
Q3 25
$-24.4M
Q2 25
$-24.6M
Q1 25
$-33.8M
Q4 24
$-122.9M
Q3 24
$-29.4M
Q2 24
$-32.3M
Q1 24
$-33.4M
Free Cash Flow
FATE
FATE
YQ
YQ
Q4 25
$-112.0M
Q3 25
$-26.6M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
Q3 24
$-29.9M
Q2 24
$-32.4M
Q1 24
$-33.4M
FCF Margin
FATE
FATE
YQ
YQ
Q4 25
-8183.9%
Q3 25
-1526.5%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
Q3 24
-973.1%
Q2 24
-477.8%
Q1 24
-1736.9%
Capex Intensity
FATE
FATE
YQ
YQ
Q4 25
434.8%
Q3 25
126.5%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
Q3 24
16.1%
Q2 24
0.8%
Q1 24
4.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons